Fig. 2 | Scientific Reports

Fig. 2

From: Identification of novel DYRK1A inhibitors as treatment options for alzheimer’s disease through comprehensive in silico approaches

Fig. 2Fig. 2

2D representation of molecular interaction of side chains of the amino acid residues in the active site of DYRK1A and the atoms of the hit compounds. (a) 10-Formyl-3,9-dihydroxy-4-(hydroxymethyl)−1,7-dimethyl-6-methylidenebenzo[b]1,4benzodioxepine-2-carboxylic acid (45934388), (b) 7-[4-hydroxy-3-(hydroxymethoxy)phenyl]−1-(4-hydroxy-3-methoxyphenyl)hept-4-en-3-one (CNP0344929), (c) Aliarin (CNP0360040), (d) NSC695598 (CNP0309850), (e) Wailupemycin L (CNP0426983), and (f) Abemaciclib (46220502).

Back to article page